MX2015001677A - Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion. - Google Patents

Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion.

Info

Publication number
MX2015001677A
MX2015001677A MX2015001677A MX2015001677A MX2015001677A MX 2015001677 A MX2015001677 A MX 2015001677A MX 2015001677 A MX2015001677 A MX 2015001677A MX 2015001677 A MX2015001677 A MX 2015001677A MX 2015001677 A MX2015001677 A MX 2015001677A
Authority
MX
Mexico
Prior art keywords
treatment
growth factors
composition
compositions
neurodegenerative disorders
Prior art date
Application number
MX2015001677A
Other languages
English (en)
Other versions
MX357828B (es
Inventor
Aldecoa Eduardo Anitua
Original Assignee
Biotechnology Inst I Mas D Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49111229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015001677(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotechnology Inst I Mas D Sl filed Critical Biotechnology Inst I Mas D Sl
Publication of MX2015001677A publication Critical patent/MX2015001677A/es
Publication of MX357828B publication Critical patent/MX357828B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención tiene como objeto el tratamiento de enfermedades neurodegenerativas u otras patologías aplicables mediante la aplicación intranasal de una composición obtenida a partir de al menos un compuesto sanguíneo con factores de crecimiento, o mediante una sustancia terapéutica obtenida a partir de dicha composición, así como la propia composición. Se garantiza que la composición alcanza el sistema nervioso central de forma eficaz desde el punto de vista del tratamiento y al mismo tiempo de forma segura para el paciente.
MX2015001677A 2012-08-09 2013-07-19 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. MX357828B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201200810A ES2442242B1 (es) 2012-08-09 2012-08-09 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
PCT/ES2013/000176 WO2014023860A1 (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento obtenidos a partir del plasma sanguíneo destinada al tratamiento de enfermedades neurodegenerativas

Publications (2)

Publication Number Publication Date
MX2015001677A true MX2015001677A (es) 2015-04-10
MX357828B MX357828B (es) 2018-07-25

Family

ID=49111229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001677A MX357828B (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.

Country Status (17)

Country Link
US (2) US20140044795A1 (es)
EP (1) EP2883569B1 (es)
JP (1) JP6339568B2 (es)
KR (1) KR102149162B1 (es)
CN (1) CN104519961A (es)
AR (1) AR092086A1 (es)
BR (1) BR112015002760A2 (es)
CA (1) CA2881075A1 (es)
CL (1) CL2014003510A1 (es)
CO (1) CO7170177A2 (es)
ES (2) ES2442242B1 (es)
IN (1) IN2014MN02675A (es)
MX (1) MX357828B (es)
PE (1) PE20150616A1 (es)
RU (1) RU2696497C2 (es)
TW (1) TWI649084B (es)
WO (1) WO2014023860A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531489A (ja) * 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系への神経栄養剤の投与
AR022333A1 (es) 1999-01-26 2002-09-04 Anitua Aldecoa Eduardo Regenerador de tejido oseo
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
ES2221770B2 (es) 2002-04-19 2006-07-16 Eduardo Anitua Aldecoa Metodo de preparacion de un compuesto para la regeneracion de tejidos.
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
US20090317377A1 (en) * 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
CA2687505C (en) * 2007-06-08 2013-10-08 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
ES2333498B1 (es) * 2007-08-02 2011-01-10 Biotechnology Institute, I Mas D, S.L. Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto.
JP2010539123A (ja) * 2007-09-14 2010-12-16 エスシーアイエル テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 変性疾患の処置のための神経内分泌因子
ES2780057T3 (es) 2009-05-14 2020-08-21 Biotechnology Institute I Mas D Sl Método para la preparación de al menos un compuesto a partir de sangre, y dispositivos de muestreo para ser utilizado en la ejecución de dicho método
KR101114712B1 (ko) * 2009-10-23 2012-02-29 세원셀론텍(주) 염화칼슘용액과 제1형 콜라겐으로 혈소판풍부혈장(ｐｒｐ)을 활성화하여 조직재생을 유도하는 조성물의 제조방법
ES2369945B1 (es) 2011-07-29 2012-10-15 Eduardo Anitua Aldecoa Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento.

Also Published As

Publication number Publication date
AR092086A1 (es) 2015-03-25
KR102149162B1 (ko) 2020-08-31
WO2014023860A1 (es) 2014-02-13
IN2014MN02675A (es) 2015-08-28
ES2442242A1 (es) 2014-02-10
CA2881075A1 (en) 2014-02-13
US20160184360A1 (en) 2016-06-30
JP6339568B2 (ja) 2018-06-06
CL2014003510A1 (es) 2015-05-04
PE20150616A1 (es) 2015-05-25
ES2662385T3 (es) 2018-04-06
CO7170177A2 (es) 2015-01-28
MX357828B (es) 2018-07-25
BR112015002760A2 (pt) 2020-04-22
EP2883569B1 (en) 2017-12-20
TWI649084B (zh) 2019-02-01
ES2442242B1 (es) 2014-11-25
KR20150040860A (ko) 2015-04-15
RU2696497C2 (ru) 2019-08-02
TW201408310A (zh) 2014-03-01
RU2015104076A (ru) 2016-09-27
US20140044795A1 (en) 2014-02-13
EP2883569A1 (en) 2015-06-17
JP2015524464A (ja) 2015-08-24
CN104519961A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
EP3180009A4 (en) Zoledronic acid dosage forms for the treatment of pain
EP3399972A4 (en) LOW DOSE THERAPEUTIC TREATMENT
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
EP3429605A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
IN2014DN06792A (es)
EP3273955A4 (en) TREATMENT OF RESPIRATORY DISEASES
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
EA201691567A1 (ru) Способы лечения легких травм головного мозга
IL282643A (en) Soft combinations for the treatment of hematological diseases
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
EP3619204A4 (en) COMPOUNDS FOR TREATING RESPIRATORY DISEASES
IL259381B (en) Miravegron for the treatment of retinal diseases
MX2015001677A (es) Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion.
EP3310396A4 (en) THERAPEUTIC HYDROGELS BASED ON NANOFIBRES FOR THE LOCAL TREATMENT OF BRAIN DISEASES
HK1209118A1 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
EP3284475A4 (en) Agent for prevention or treatment of corneal disorders
GB201604359D0 (en) Treatment of tissue disorders
GB2553686A8 (en) Ethynylxanthines, preparation and use as calcium ion channel modulators

Legal Events

Date Code Title Description
FG Grant or registration